The domestic pharmaceutical and biotech industries are turning their attention to the global stage ahead of the 2026 American Society of Clinical Oncology (ASCO) conference, scheduled to take place in Chicago from May 29 to June 2. This year's ASCO is expected to serve as a litmus test for K-Bio, determining whether it can translate participation into concrete business outcomes such as licensing deals and mergers and acquisitions (M&A).
According to industry sources, ASCO is recognized as the world's largest oncology conference and a key platform for unveiling clinical trial results in new drug development. With major global pharmaceutical companies shifting their collaboration strategies to focus on 'clinically validated data,' firms are seizing opportunities to present phased clinical results at the conference to secure global partnerships.
GI Innovation's immuno-oncology drug GI-101A has been selected for a rapid oral presentation at ASCO 2026 based solely on its Phase 1 data. The company emphasizes the efficacy of its combination therapy with PD-1 antibody drugs, adopting a strategic clinical design from the early stages. The oral presentation at this stage is considered unusual within the domestic biotech sector.
ImmuneOncia will present interim results from its Phase 1b trial of the next-generation CD47 antibody IMC-002 targeting triple-negative breast cancer (TNBC) in a poster session. This substantial data release is expected to lay the groundwork for discussions on expanding indications and forming global partnerships.
TiumBio will showcase interim results from its Phase 2a trial of the oral immuno-oncology drug Tosefertinib (TU2218) in combination with Keytruda for head and neck cancer in a poster. Tosefertinib is being developed to improve the tumor microenvironment by simultaneously inhibiting transforming growth factor (TGF)-beta and vascular endothelial growth factor (VEGF). The company plans to update response rates and survival analysis results at ASCO, following data presented at last year's Society for Immunotherapy of Cancer (SITC) conference.
VigenCell will present oral results from its Phase 2 trial of the cell therapy 'VT-EBV-N.' The company intends to focus on the clinical achievements of VT-EBV-N in terms of reducing recurrence and extending survival, highlighting significant effects in these areas and suggesting improved patient prognosis.
Additionally, SillaJen will announce results from its Phase 1 trial of the dual inhibitor 'BAL0891' targeting solid tumors and acute myeloid leukemia (AML). The data will focus on the tolerability and initial response rates of both monotherapy and combination therapy with PD-1 antibodies and chemotherapy. STCube will present early data from its Phase 1b/2 trial (STCUBE-003) of the BTN1A1-targeted immuno-oncology drug 'Nelmastobat' for metastatic colorectal cancer in a poster session, aiming to demonstrate disease control effects and potential survival improvements in patients with high BTN1A1 expression through multiplex immunohistochemistry (mIHC) analysis.
An industry insider noted, "ASCO is seen as an opportunity not just for showcasing technological capabilities, but also for potentially reshaping the landscape of licensing deals and M&A with major global pharmaceutical companies. It presents a chance to establish a full value chain that leads to collaboration and global commercialization with these firms."
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.